Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SRPT Sarepta Therapeutics

盘前交易 02-24 04:16:12 EST

18.12

-0.76

-4.03%

最高19.01	最低18.02	成交量125.29万
今开18.72	昨收18.88	日振幅5.24%
总市值18.99亿	流通市值17.24亿	总股本1.05亿
成交额2,285万	换手率1.32%	流通股本9,517万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SRPT","market":"US","secType":"STK","nameCN":"Sarepta Therapeutics","latestPrice":18.12,"timestamp":1771880400000,"preClose":18.88,"halted":0,"volume":1252885,"delay":0,"changeRate":-0.04025423728813549,"floatShares":95167800,"shares":104787187,"eps":-2.771059,"marketStatus":"盘前交易","change":-0.76,"latestTime":"02-24 04:16:12 EST","open":18.72,"high":19.01,"low":18.02,"amount":22848469.086225003,"amplitude":0.052436,"askPrice":18.72,"askSize":258,"bidPrice":17.45,"bidSize":158,"shortable":3,"etf":0,"ttmEps":-2.771059,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771943400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":865396800000,"exchange":"NASDAQ","adjPreClose":18.12,"postHourTrading":{"tag":"盘后","latestPrice":18.25,"preClose":18.12,"latestTime":"19:54 EST","volume":26521,"amount":480670.9595,"timestamp":1771894488990,"change":0.13,"changeRate":0.007174,"amplitude":0.008278},"volumeRatio":0.791726,"impliedVol":1.0488,"impliedVolPercentile":0.752},"requestUrl":"/m/hq/s/SRPT/tweets","defaultTab":"tweets","newsList":[{"id":"1111784682","title":"财报前瞻｜Sarepta Therapeutics本季度营收预计降37.55%，机构观点偏看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1111784682","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111784682?lang=zh_cn&edition=full","pubTime":"2026-02-18 13:18","pubTimestamp":1771391931,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics将于2026年02月25日发布最新季度财报，市场关注营收与利润的下行压力及管线进展对商业化前景的影响。市场一致预期本季度营收为3.92亿美元，同比下降37.55%；调整后每股收益为-1.31美元，同比下降169.25%，公司未披露毛利率、净利润或净利率的具体预测，上季度财报亦未给出针对本季度的收入指引。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Sarepta Therapeutics本季度营收预计降37.55%，机构观点偏看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT"],"gpt_icon":0},{"id":"1161367306","title":"Sarepta Therapeutics宣布其亨廷顿病在研疗法SRP-1005临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1161367306","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161367306?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:32","pubTimestamp":1770211938,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics公司近日宣布，其针对亨廷顿病的在研治疗药物SRP-1005的临床试验申请已正式获得监管机构批准。这一进展标志着该创新疗法向临床研究阶段迈出了关键一步，为后续开发奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE0009355771.USD","SRPT","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4139"],"gpt_icon":0},{"id":"1156120240","title":"Sarepta Therapeutics公司SRP-1005（代号Insightt）首次人体临床试验预计2026年第二季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1156120240","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156120240?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:31","pubTimestamp":1770211880,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics公司宣布，其研发的创新疗法SRP-1005（内部代号Insightt）计划于2026年第二季度开展首次人体临床试验。这项重要进展标志着该药物正式迈入临床研究阶段，为后续开发奠定基础。\n作为公司管线中的重点候选药物，SRP-1005的临床试验启动将遵循严格的科学规范与伦理标准。此次研究旨在评估该疗法在人体中的安全性、耐受性及初步疗效，为未来更大规模的临床研究提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0002141913.USD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4585","SRPT","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"1110874705","title":"Sarepta Therapeutics股价盘前大涨6.7% 公司公布杜氏肌营养不良基因疗法三年数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1110874705","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110874705?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:28","pubTimestamp":1769434092,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics股价在盘前交易中强势攀升6.7%，此前该公司公布了其针对杜氏肌营养不良症的基因疗法为期三年的临床数据。这一积极的市场反应凸显了投资者对该疗法长期疗效潜力的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE0009355771.USD","SRPT","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4139"],"gpt_icon":0},{"id":"1162536674","title":"Sarepta公布EMBARK三年期研究积极顶线结果：Elevidys显著延缓杜氏肌营养不良症患者关键功能指标恶化","url":"https://stock-news.laohu8.com/highlight/detail?id=1162536674","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162536674?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:04","pubTimestamp":1769432659,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics宣布，其针对ambulatory杜氏肌营养不良症患者开展的EMBARK三年期研究取得积极顶线结果。数据显示，基因疗法Elevidys在关键功能指标上显著延缓了疾病进展。这项长期研究结果进一步验证了该疗法对患者运动功能的持久保护作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE0002141913.USD","SRPT","IE00B2B36J28.USD","BK4585","IE0009355771.USD","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"1157535048","title":"Sarepta Therapeutics 股价盘前大涨 6%，公司将公布肌肉萎缩症基因疗法三年期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1157535048","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157535048?lang=zh_cn&edition=full","pubTime":"2026-01-26 19:15","pubTimestamp":1769426117,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics 股价在盘前交易中攀升 6%，该公司即将发布其针对肌肉萎缩症的基因疗法的三年期临床数据。\n这一积极的市场反应凸显了投资者对该基因疗法长期疗效数据的高度期待。三年期数据的公布将为评估该疗法的持久性与安全性提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","BK4585","IE00BJT1NW94.SGD","IE0009355771.USD","BK4139","IE00BFTCPJ56.SGD","SRPT","IE00BJJMRZ35.SGD","IE0002141913.USD"],"gpt_icon":0},{"id":"1123806962","title":"Sarepta Therapeutics将公布Elevidys基因疗法在杜氏肌营养不良症患者中的三年期关键数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1123806962","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123806962?lang=zh_cn&edition=full","pubTime":"2026-01-24 05:05","pubTimestamp":1769202312,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics即将披露其基因疗法Elevidys针对能够行走的杜氏肌营养不良症患者的三年度核心研究数据。这项名为Embark的临床试验结果，将为该疗法的长期疗效与安全性提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE00B2B36J28.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","SRPT","BK4585","BK4139","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"1176595326","title":"Sarepta Therapeutics提交亨廷顿病候选疗法SRP-1005临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1176595326","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176595326?lang=zh_cn&edition=full","pubTime":"2026-01-07 21:31","pubTimestamp":1767792701,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics宣布，已正式提交其亨廷顿病在研疗法SRP-1005的临床试验申请。这一进展标志着该公司在神经退行性疾病治疗领域的战略布局迈出关键一步。作为基因医学领域的先锋企业，Sarepta此次申报的疗法旨在通过创新机制靶向亨廷顿病的病理根源。若获批临床，SRP-1005有望为全球罕见神经系统疾病患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","SRPT","IE00BJJMRZ35.SGD","BK4139","IE0002141913.USD","BK4585","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"1127867080","title":"美股生物医药股集体上扬！Moderna涨超7%，Sarepta Therapeutics涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127867080","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127867080?lang=zh_cn&edition=full","pubTime":"2026-01-06 23:04","pubTimestamp":1767711863,"startTime":"0","endTime":"0","summary":"1月6日，美股生物医药股集体上扬，$Moderna(MRNA)$涨超7%，$Sarepta Therapeutics(SRPT)$涨超6%，$诺和诺德(NVO)$、$诺瓦瓦克斯医药(NVAX)$涨超5%，$葛兰素史克(GSK)$涨超4%。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"65ea9bea0b0ef90fd686d76394fa8759","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","BK4007","IE0002141913.USD","MRNA","SRPT","IE00B2B36J28.USD","BK4539","BK4585","IE0009355771.USD","NVO","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"1186034314","title":"Sarepta Therapeutics宣布约2.91亿美元1.25%可转换高级票据再融资，至2027年到期","url":"https://stock-news.laohu8.com/highlight/detail?id=1186034314","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186034314?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:02","pubTimestamp":1765454537,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics宣布约2.91亿美元1.25%可转换高级票据的再融资，至2027年到期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","SRPT","IE00BJJMRZ35.SGD","BK4585","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE0002141913.USD"],"gpt_icon":0},{"id":"2590329256","title":"Wedbush表示Sarepta的抛售“过度”。","url":"https://stock-news.laohu8.com/highlight/detail?id=2590329256","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590329256?lang=zh_cn&edition=full","pubTime":"2025-12-10 04:26","pubTimestamp":1765311960,"startTime":"0","endTime":"0","summary":"Sarepta（SRPT）美股周二尾盘上涨1.7%，此前券商Wedbush称Sarepta的股票抛售行为“过头了”。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-10/doc-inhahafp2378077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B2B36J28.USD","IE0009355771.USD","IE00BJT1NW94.SGD","SRPT","BK4139","IE0002141913.USD","BK4585","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","SINA"],"gpt_icon":0},{"id":"1110568516","title":"Sarepta Therapeutics：计划在年底前启动第8组，并预计在2026年下半年完成主要终点数据收集","url":"https://stock-news.laohu8.com/highlight/detail?id=1110568516","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110568516?lang=zh_cn&edition=full","pubTime":"2025-11-25 22:01","pubTimestamp":1764079281,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics：计划在年底前启动第8组，并预计在2026年下半年完成主要终点数据收集","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","BK4139","BK4585","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","SRPT","IE0009355771.USD","IE0002141913.USD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"1192840225","title":"Sarepta 提供关于 Srp-1003 的进展更新，这是一种用于肌强直性肌肉病 1 型的研究性 siRNA 治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1192840225","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192840225?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:31","pubTimestamp":1763987488,"startTime":"0","endTime":"0","summary":"Sarepta 提供关于 Srp-1003 的进展更新，这是一种用于肌强直性肌肉病 1 型的研究性 siRNA 治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","SRPT","IE00B2B36J28.USD","IE0002141913.USD","IE0009355771.USD","BK4585","BK4139"],"gpt_icon":0},{"id":"1197238185","title":"Hhs：新的Elevidys安全警告将适应症限制在4岁及以上、具有DMD基因确认突变的步态患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1197238185","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197238185?lang=zh_cn&edition=full","pubTime":"2025-11-15 03:07","pubTimestamp":1763147266,"startTime":"0","endTime":"0","summary":"Hhs：新的Elevidys安全警告将适应症限制在4岁及以上、具有DMD基因确认突变的步态患者","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","SRPT","BK4139","IE00BFTCPJ56.SGD","BK4585"],"gpt_icon":0},{"id":"1178897853","title":"卫生与公共服务部：FDA批准新的安全警告及修订指示，限制Elevidys的使用","url":"https://stock-news.laohu8.com/highlight/detail?id=1178897853","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178897853?lang=zh_cn&edition=full","pubTime":"2025-11-15 03:00","pubTimestamp":1763146813,"startTime":"0","endTime":"0","summary":"卫生与公共服务部：FDA批准新的安全警告及修订指示，限制Elevidys的使用，以应对致命肝损伤的报告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4139","IE0002141913.USD","SRPT","IE0009355771.USD","BK4585","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2583063718","title":"Sarepta Therapeutics, Inc.盘中异动 临近午盘股价大涨5.11%报18.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583063718","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583063718?lang=zh_cn&edition=full","pubTime":"2025-11-15 00:30","pubTimestamp":1763137818,"startTime":"0","endTime":"0","summary":"北京时间2025年11月15日00时30分，Sarepta Therapeutics, Inc.股票出现异动，股价大幅上涨5.11%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.22%。其相关个股中，Cidara Therapeutics, Inc.、Cypherpunk Technologies Inc.、Invivyd, Inc.涨幅较大，Aspire Biopharma Holdings, Inc.、Cypherpunk Technologies Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为980.06%、247.23%、137.65%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Cypherpunk Technologies Inc.、Hcw Biologics Inc.，振幅分别为101.46%、94.31%、59.44%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115003018a4a209fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115003018a4a209fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4539","IE00BFTCPJ56.SGD","BK4585","BK4139","IE0002141913.USD","SRPT","BK4007","IE0009355771.USD","IE00BJJMRZ35.SGD","LENZ"],"gpt_icon":0},{"id":"1154277843","title":"异动解读 | 瑞穗证券上调评级，Sarepta Therapeutics盘中大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154277843","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154277843?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:55","pubTimestamp":1762354544,"startTime":"0","endTime":"0","summary":"生物制药公司Sarepta Therapeutics今日盘中大涨5.12%，引发市场广泛关注。根据最新报告，瑞穗证券将Sarepta Therapeutics的投资评级上调至\"跑赢大盘\"，同时将目标价从19美元大幅上调至26美元，涨幅高达36.8%。Sarepta Therapeutics作为一家专注于开发用于治疗罕见疾病的创新疗法的生物制药公司，在基因治疗领域具有较强的竞争力。这次评级的提升不仅可能吸引更多投资者关注该公司，还可能为Sarepta Therapeutics后续的融资和业务发展创造有利条件。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SRPT"],"gpt_icon":0},{"id":"1112951067","title":"异动解读 | 瑞穗证券上调评级，Sarepta Therapeutics盘前大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112951067","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112951067?lang=zh_cn&edition=full","pubTime":"2025-11-05 18:04","pubTimestamp":1762337070,"startTime":"0","endTime":"0","summary":"周三盘前，生物制药公司Sarepta Therapeutics股价大涨5.06%，引发市场关注。此次股价上涨主要受益于华尔街知名投资银行瑞穗证券对该公司的积极评价。根据最新报告，瑞穗证券将Sarepta Therapeutics的投资评级上调至\"跑赢大盘\"，同时将目标价从19美元大幅上调至26美元，这一举动显著提振了投资者信心。瑞穗证券的评级上调反映了分析师对Sarepta Therapeutics未来发展前景的看好。作为一家专注于开发用于治疗罕见疾病的创新疗法的生物制药公司，Sarepta Therapeutics在基因治疗领域具有较强的竞争力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SRPT"],"gpt_icon":0},{"id":"1178760479","title":"Sarepta Therapeutics Inc：瑞穗证券将投资评级上调至“跑赢大盘”，目标价从19美元上调至26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1178760479","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178760479?lang=zh_cn&edition=full","pubTime":"2025-11-05 18:03","pubTimestamp":1762336993,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics Inc：瑞穗证券将投资评级上调至“跑赢大盘”，目标价从19美元上调至26美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4139","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4585","SRPT","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"1114173553","title":"异动解读 | Sarepta Therapeutics股价夜盘暴跌5.06%，肌肉疾病新药确证试验失败","url":"https://stock-news.laohu8.com/highlight/detail?id=1114173553","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114173553?lang=zh_cn&edition=full","pubTime":"2025-11-05 09:29","pubTimestamp":1762306182,"startTime":"0","endTime":"0","summary":"美国生物技术公司Sarepta Therapeutics周二夜盘股价大跌5.06%，引发市场广泛关注。根据公司最新公布的消息，Sarepta Therapeutics一款已获批准的针对杜氏肌营养不良症的靶向基因疗法药物在确证性试验中未能达到主要目标。杜氏肌营养不良症是一种罕见的遗传性肌肉退化疾病，目前尚无根治方法。Sarepta的这款药物曾被寄予厚望，有望为患者带来新的治疗选择。市场对这一负面消息反应强烈，导致公司股价在夜盘交易中大幅下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SRPT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sarepta.com","stockEarnings":[{"period":"1week","weight":0.0185},{"period":"1month","weight":-0.1425},{"period":"3month","weight":-0.0636},{"period":"6month","weight":0.0028},{"period":"1year","weight":-0.8295},{"period":"ytd","weight":-0.158}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sarepta Therapeutics, Inc.于1980年7月22日在俄勒冈州注册成立。该公司是一家商业阶段的生物制药公司，专注于通过发现和开发独特的RNA靶向疗法、基因疗法和其他用于治疗罕见疾病的基因治疗模式来帮助患者。应用他们的专有、高度差异化和创新技术，并通过与战略合作伙伴的合作，该公司开发了多个获批产品，用于治疗杜氏肌营养不良症，并正在为广泛的疾病和紊乱开发潜在的候选治疗药物，包括杜氏、肢带型肌营养不良症和其他与神经肌肉和中枢神经系统相关的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.052169},{"month":2,"riseRate":0.571429,"avgChangeRate":0.03507},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.008053},{"month":4,"riseRate":0.307692,"avgChangeRate":0.010895},{"month":5,"riseRate":0.692308,"avgChangeRate":0.132774},{"month":6,"riseRate":0.692308,"avgChangeRate":0.049251},{"month":7,"riseRate":0.307692,"avgChangeRate":-0.004395},{"month":8,"riseRate":0.714286,"avgChangeRate":0.085094},{"month":9,"riseRate":0.571429,"avgChangeRate":0.128993},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.068917},{"month":11,"riseRate":0.714286,"avgChangeRate":0.074513},{"month":12,"riseRate":0.571429,"avgChangeRate":0.010915}],"exchange":"NASDAQ","name":"Sarepta Therapeutics","nameEN":"Sarepta Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Sarepta Therapeutics,SRPT,Sarepta Therapeutics股票,Sarepta Therapeutics股票老虎,Sarepta Therapeutics股票老虎国际,Sarepta Therapeutics行情,Sarepta Therapeutics股票行情,Sarepta Therapeutics股价,Sarepta Therapeutics股市,Sarepta Therapeutics股票价格,Sarepta Therapeutics股票交易,Sarepta Therapeutics股票购买,Sarepta Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}